A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility
about
Multiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attackTriple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDPreventive aspects in peripheral artery disease.Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention.Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbiAntiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
P2860
Q24201386-2282B5AA-E190-4EBF-82E2-62584B089A50Q33390176-35B58A4D-EF2D-4572-BDA0-AE7094631F68Q35538299-0A0B139D-90A1-4D18-9F6F-9D5AFD121D39Q36866370-98206FA9-37A9-4A87-90BE-7C69B3952983Q37984281-58BA8BD9-AA25-4988-810E-2A12021406E1Q38570750-D5D4A56E-035F-43AC-9507-F5CB2E05EA97Q38896828-F03695AB-4C84-4211-9D9D-5005595E843BQ42690507-BA3D5248-90AF-4526-91D2-DEE875911875Q47254205-39A3D5AF-37A5-435F-8251-390A07A0A34F
P2860
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A randomised controlled trial ...... , tolerability and feasibility
@ast
A randomised controlled trial ...... , tolerability and feasibility
@en
A randomised controlled trial ...... , tolerability and feasibility
@en-gb
A randomised controlled trial ...... , tolerability and feasibility
@nl
type
label
A randomised controlled trial ...... , tolerability and feasibility
@ast
A randomised controlled trial ...... , tolerability and feasibility
@en
A randomised controlled trial ...... , tolerability and feasibility
@en-gb
A randomised controlled trial ...... , tolerability and feasibility
@nl
altLabel
A Randomised Controlled Trial ...... , Tolerability and Feasibility
@en
prefLabel
A randomised controlled trial ...... , tolerability and feasibility
@ast
A randomised controlled trial ...... , tolerability and feasibility
@en
A randomised controlled trial ...... , tolerability and feasibility
@en-gb
A randomised controlled trial ...... , tolerability and feasibility
@nl
P2093
P2860
P50
P1433
P1476
A randomised controlled trial ...... , tolerability and feasibility
@en
P2093
Gillian M Sare
Mark R Willmot
P2860
P356
10.1371/JOURNAL.PONE.0002852
P407
P577
2008-01-01T00:00:00Z